Baptist Health Herbert Wertheim Cancer Institute Becomes a Care Partner of Memorial Sloan Kettering Cancer Center (MSK)
-
By
-
November 19, 2026
-
4 min
By
November 19, 2026
by
November 19, 2026
Vincent (Wenxin) Xu, MD , shows among patients with advanced kidney cancer on immunotherapy alone, KIM-1 reductions were seen in immune-inflamed tumors, while no KIM-1 drop was linked to immune-depleted tumors.
November 17, 2026
Final analysis of the pivotal KEYNOTE-564 trial in kidney cancer presented by Toni Choueiri, MD. After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival and overall survival in high-risk clear-cell renal cell carcinoma.
November 17, 2026